Blockchain Registration Transaction Record

Profound Medical Secures $36M to Advance AI-Powered Prostate Treatment

Profound Medical raises $36M to expand AI-guided prostate treatment TULSA-PRO, a non-invasive therapy for cancer and BPH. Funding supports sales growth and R&D.

This funding enables Profound Medical to accelerate the commercialization of its TULSA-PRO system, a groundbreaking non-invasive therapy for prostate diseases. For patients, this means access to a safer, more precise treatment option that preserves urinary and sexual function, reduces recovery time, and eliminates radiation exposure. As prostate cancer and BPH affect millions globally, this innovation could transform standard care, offering a less traumatic alternative to surgery or radiation. The expansion of such technologies also signals a shift toward personalized, AI-driven medicine, potentially lowering healthcare costs and improving quality of life for those with chronic conditions.